Early Phase 1 Refractory Clinical Trials
43 recruitingEarly Phase 1
What is a Early Phase 1 trial?
Early Phase 1 trials are the earliest stage of testing in humans. These small studies focus on how a drug is processed in the body and how it affects the body, often enrolling just a handful of participants to establish initial safety data.
Showing 1–20 of 43 trials
Recruiting
Early Phase 1
CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms
Relapsed or Refractory Plasma Cell Neoplasms
The General Hospital of Western Theater Command20 enrolled1 locationNCT07519187
Recruiting
Early Phase 1
A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
Relapsed/Refractory Large B-Cell Lymphoma
Shenzhen Fosun Kairos Biotechnology Co., Ltd.12 enrolled6 locationsNCT07606937
Recruiting
Early Phase 1
Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
AL AmyloidosisSystemic Light Chain AmyloidosisRelapsed/Refractory Light Chain Amyloidosis
Beijing Boren Hospital30 enrolled1 locationNCT07626476
Recruiting
Early Phase 1
A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases
Moderate to Severe Refractory Autoimmune Diseases
Vivacta Biotechnology (Shanghai) Co., Ltd.22 enrolled1 locationNCT07614191
Recruiting
Early Phase 1
IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE)
Refractory Systemic Lupus Erythematosus
Peking University People's Hospital18 enrolled1 locationNCT07617740
Recruiting
Early Phase 1
A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases
Moderate to Severe Refractory Autoimmune Disease
Grit Biotechnology22 enrolled1 locationNCT07333118
Recruiting
Early Phase 1
An Open-label, Single-arm, Multicenter Phase II Clinical Study of Azacitidine, Chidamide Combined With PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma.
Peripheral T-Cell Lymphoma Refractory
Second Affiliated Hospital of Soochow University30 enrolled1 locationNCT07598578
Recruiting
Early Phase 1
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Relapsing or Refractory Multiple Sclerosis (MS)Myasthenia Gravis (MG)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)+1 more
Tongji Hospital36 enrolled1 locationNCT07337785
Recruiting
Early Phase 1
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
Steroid refractory Graft Versus Host DiseaseHematopoietic and Lymphoid Cell Neoplasm
M.D. Anderson Cancer Center24 enrolled1 locationNCT04744116
Recruiting
Early Phase 1
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma
Suzhou Immunofoco Biotechnology Co., Ltd30 enrolled4 locationsNCT07376642
Recruiting
Early Phase 1
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Suzhou Immunofoco Biotechnology Co., Ltd30 enrolled4 locationsNCT07493135
Recruiting
Early Phase 1
A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases
Relapsed/Refractory Autoimmune Diseases
Beijing Boren Hospital18 enrolled1 locationNCT07448298
Recruiting
Early Phase 1
An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease
Relapsed/Refractory Immune NephropathyRelapsed/Refractory Immune-mediated Kidney Disease
Changhai Hospital36 enrolled1 locationNCT07241468
Recruiting
Early Phase 1
Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center9 enrolled1 locationNCT05800405
Recruiting
Early Phase 1
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases
IgA Nephropathy (IgAN)Membranous NephropathyANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN)+2 more
Grit Biotechnology30 enrolled1 locationNCT07389499
Recruiting
Early Phase 1
Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases
Relapsed/Refractory B Cell-Mediated Autoimmune Diseases
Ruijin Hospital27 enrolled1 locationNCT07322718
Recruiting
Early Phase 1
Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma
Multiple MyleomaRefractory and Relapsed Multiple Myeloma
Wondercel Biotech (ShenZhen)30 enrolled1 locationNCT06663046
Recruiting
Early Phase 1
the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
Recurrent or Refractory Systemic Lupus ErythematosusRecurrent or Refractory IgG4 Related DiseasesRecurrent or Refractory Systemic Sclerosis+2 more
Tongji Hospital45 enrolled1 locationNCT07339540
Recruiting
Early Phase 1
A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
Relapsed/Refractory Autoimmune Diseases
Nanjing Legend Biotech Co.36 enrolled5 locationsNCT07095075
Recruiting
Early Phase 1
Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies
Relapsed/Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology6 enrolled1 locationNCT07240974